Table 1.

Prospective studies evaluating first-line S-1 combined with platinum agents.

Study	Phase	Schedule	n	MST (months)	1-year survival (%)	Response rate (%)
S-1 and CDDP (cisplatin)
[Ichinose et al. 2004]	II	S-1; 40 mg/m2, bid, days 1–21	55	11	45	47
		CDDP; 60 mg/m2, day 8,
		Q 35 days
[Kubota et al. 2010]	I/II	S-1; 40 mg/m2, bid, days 1–14	55	18.1	65.2	32.7
		CDDP; 60 mg/m2, day 1,
		Q 21 days*
[Sandler et al. 2011]	II	S-1; 25 mg/m2, bid, days 1–14	58	4.0 (PFS)	–	23.2
		CDDP; 75 mg/m2, day 1,
		Q 21 days
[Katakami et al. 2012] CATS	III	S-1; 40 mg/m2, bid, days 1–21	303	16.1	–	26.9
		CDDP; 60 mg/m2, day 8,
		Q 35 days
		DTX; 60 mg/m2, day 1	305	17.1	–	31.3
		CDDP; 80 mg/m2, day 1
		Q 21 days
S-1 and CBDCA (carboplatin)
[Tamura et al. 2009]	I/II	S-1; 40 mg/m2, bid, days 1–14	19	11.1	–	30.8
		CBDCA AUC 5, day 1,
		Q 21 days*
[Kaira et al. 2009]	II	S-1; 40 mg/m2, bid, days 1–14	29	16.0	62.6	31.0
		CBDCA AUC 5, day 1,
		Q 28 days
[Okamoto et al. 2010] LETS	III	S-1; 40 mg/m2, bid, days 1–14	282	15.2	57.3	20.4
		CBDCA AUC 5, day 1,
		Q 21 days
		PTX 200 mg/m2, day 1	281	13.3	55.5	29.0
		CBDCA AUC 6, day 1
		Q 21 days

AUC, area under the curve; bid, twice daily; DTX, docetaxel; MST, median survival time; PFS, progression-free survival.

^*Recommended dose for phase II study.